Default company panoramic image


Transforming cancer therapy by precise delivery of drugs into cancer cells, greatly increasing treatment efficacy with reduced side effects

  • Stage Product In Development
  • Industry Biotechnology
  • Location London, GB-ENG, United Kingdom
  • Currency GBP
  • Founded June 2006
  • Employees 5
  • Website

Company Summary

BioMoti exists to transform the lives of cancer patients by doing things differently. Oncojans™ are a new class of therapeutic microparticles that target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. MOTI1001 is BioMoti’s lead Oncojan™ based ovarian cancer candidate that has shown very promising potential in early preclinical studies.


  • Default avatar
    Davidson Ateh

    Dr Davidson Ateh (co-founder and CEO) is an entrepreneur operating in the life sciences. He has an interdisciplinary scientific background in bioengineering and was a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship.

  • Default avatar
    Keith Powell

    Dr Keith Powell (Chairman) has been in biotech since it started. He started at GSK and ICI/Zeneca leading several large groups, then joined Maxygen on the West Coast of the USA, growing a business that eventually spun out as “Codexis”. On his return to the UK he worked with the Bloomsbury BioSeed Fund and Longbow Capital leading portfolio companies including Polytherics. He is currently Chairman of Domainex and Canbex.

  • Default avatar
    Jo Martin

    Jo is the NHS National Clinical Director of Pathology, Director of Academic Health Sciences (and Consultant Histopathologist) at Barts Health NHS Trust and Professor of Pathology at Queen Mary University of London. She has a track record running a large NHS Trust Division (£89 million budget per annum), delivering and commissioning major projects. She was part of the assessment team on early stage technologies for Nikko Principal Investments.


  • Default avatar
    Fasken Martineau
    Default avatar
    Rawlinson and Hunter

Previous Investors

  • Default avatar
    Oxford Technology